| Divya R Kini Md Inc | |
|
1500 Southgate Avenue Divya Kini Md Inc Suite 204 Daly City CA 94015 | |
| (650) 755-2192 | |
| (650) 745-0710 |
| Full Name | Divya R Kini Md Inc |
|---|---|
| Speciality | Family Medicine |
| Location | 1500 Southgate Avenue, Daly City, California |
| Authorized Official Name and Position | Divya R Kini (MD) |
| Authorized Official Contact | 6507552192 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Divya R Kini Md Inc 1500 Southgate Avenue Divya Kini Md Inc Suite 204 Daly City CA 94015 Ph: () - | Divya R Kini Md Inc 1500 Southgate Avenue Divya Kini Md Inc Suite 204 Daly City CA 94015 Ph: (650) 755-2192 |
| NPI Number | 1093861544 |
|---|---|
| Provider Enumeration Date | 01/26/2007 |
| Last Update Date | 02/27/2015 |
| Medicare PECOS PAC ID | 4082713482 |
|---|---|
| Medicare Enrollment ID | O20070626000618 |
News Archive
"Hope for Haiti Now" (HFHN) today announced the distribution of $35M as the first installment of funds raised through the January 22nd telethon: "Hope for Haiti Now: A Global Benefit for Earthquake Relief." Six of the telethon beneficiaries (Oxfam America, Partners In Health, the American Red Cross, UNICEF, United Nations World Food Programme, and Yele Haiti Foundation) submitted proposals last week.
The 1-month follow-up results of the Transcatheter Valve Treatment Sentinel Pilot Registry have provided data on factors associated with transcatheter aortic valve implantation, as well as short term outcomes, in Europe.
Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead investigator Dr. Daniel Sliva says, The formula we studied inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells.
Pfizer Inc. and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year.
Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093861544 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Divya R Kini |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1649354309 PECOS PAC ID: 0143329532 Enrollment ID: I20070626000538 |
News Archive
"Hope for Haiti Now" (HFHN) today announced the distribution of $35M as the first installment of funds raised through the January 22nd telethon: "Hope for Haiti Now: A Global Benefit for Earthquake Relief." Six of the telethon beneficiaries (Oxfam America, Partners In Health, the American Red Cross, UNICEF, United Nations World Food Programme, and Yele Haiti Foundation) submitted proposals last week.
The 1-month follow-up results of the Transcatheter Valve Treatment Sentinel Pilot Registry have provided data on factors associated with transcatheter aortic valve implantation, as well as short term outcomes, in Europe.
Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead investigator Dr. Daniel Sliva says, The formula we studied inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells.
Pfizer Inc. and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year.
Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.
› Verified 9 days ago
News Archive
"Hope for Haiti Now" (HFHN) today announced the distribution of $35M as the first installment of funds raised through the January 22nd telethon: "Hope for Haiti Now: A Global Benefit for Earthquake Relief." Six of the telethon beneficiaries (Oxfam America, Partners In Health, the American Red Cross, UNICEF, United Nations World Food Programme, and Yele Haiti Foundation) submitted proposals last week.
The 1-month follow-up results of the Transcatheter Valve Treatment Sentinel Pilot Registry have provided data on factors associated with transcatheter aortic valve implantation, as well as short term outcomes, in Europe.
Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead investigator Dr. Daniel Sliva says, The formula we studied inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells.
Pfizer Inc. and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year.
Merck, known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.
› Verified 9 days ago
Pediahealth Medical Group, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 901 Campus Dr, Suite 210, Daly City, CA 94015 Phone: 650-994-3000 | |
John W. Wilson, Md, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1800 Sullivan Ave, Room 503, Daly City, CA 94015 Phone: 650-994-9090 Fax: 650-994-9093 | |
Daly City Youth Hlth Ctr Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 350 90th Street, Daly City, CA 94015 Phone: 650-985-7000 Fax: 605-301-8626 | |
North East Medical Services - Eastmoor Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 211 Eastmoor Ave, Daly City, CA 94015 Phone: 415-391-9686 | |
Ellick Tsang M D Corporation Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1800 Sullivan Ave, Suite 304, Daly City, CA 94015 Phone: 650-992-8484 Fax: 650-992-8480 | |
Medisina Sa Familia, Pa, Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1850 Sullivan Ave Ste 510, Daly City, CA 94015 Phone: 650-580-6479 Fax: 650-735-5580 |